Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30257% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.DE operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Viridian Therapeutics, Inc.DE's operating cash flow for the twelve months ending Jun 30, 2026 was -$333.34M. For fiscal 2025 it was -$276.39M. The highest annual figure on record is -$1.17M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$276.39M | – |
| FY2024 | Dec 31, 2024 | -$232.32M | – |
| FY2023 | Dec 31, 2023 | -$184.17M | – |
| FY2022 | Dec 31, 2022 | -$93.84M | – |
| FY2021 | Dec 31, 2021 | -$54.58M | – |
| FY2020 | Dec 31, 2020 | -$29.78M | – |
| FY2019 | Dec 31, 2019 | -$36.06M | – |
| FY2018 | Dec 31, 2018 | -$26.84M | – |
| FY2017 | Dec 31, 2017 | -$28.17M | – |
| FY2016 | Dec 31, 2016 | -$14.76M | – |
| FY2015 | Dec 31, 2015 | -$6.90M | – |
| FY2014 | Dec 31, 2014 | -$2.21M | – |
| FY2013 | Dec 31, 2013 | -$1.17M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$105.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$119.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$84.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$75.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$92.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$73.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$67.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$46.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$45.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$38.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$45.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$61.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$34.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.67M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.63M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.54M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.79M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.46M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.27M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.17M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.18M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.51M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.36M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.24M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.66M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.29M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.84M | – |
See a number that looks wrong?